Treatment of post-COVID-19 patients with chronic recurrent prostatitis: efficacy of recombinant interferon α-2b medications

Treatment of post-COVID-19 patients with chronic recurrent prostatitis: efficacy of recombinant interferon α-2b medications

Introduction. The tactics of managing and treating patients with chronic recurrent bacterial prostatitis (CRBP) in some cases is a difficult-to-treat condition for a practicing urologist. This circumstance occurs because the disease has several predisposing factors, a complex and multifaceted pathog...

Full description

Bibliographic Details
Main Authors: Kh. S. Ibishev, Yu. L. Naboka, P. A. Krainiy, I. A. Gudima, A. D. Plyakin, J. O. Prokop, A. V. Ilyash
Format: Article
Language:Russian
Published: State Budget Educational Institute of Higher Professional Education, Rostov State Medical University, Ministry Health of Russian Federation 2023-01-01
Series:Vestnik Urologii
Subjects:
chronic bacterial prostatitis
prostate secretion
cytokines
immunotherapy
interferons
Online Access:https://www.urovest.ru/jour/article/view/623

Internet

https://www.urovest.ru/jour/article/view/623

Similar Items